Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 27, 2026, 3:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Gabapentin - 1800 mg/day Clear all

Conditions: Vulvodynia
Interventions: Placebo oral capsule, Gabapentin; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older · Female only
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Rochester, New York • Memphis, Tennessee

Conditions: Hot Flashes
Interventions: Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo; Drug
Lead sponsor: Depomed; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 45
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 42 more

Conditions: Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions: Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 7
States / cities: Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more

Conditions: Vulvar Pain Symptoms, Vulvodynia (Chronic Vulvar Pain)
Interventions: Gabapentin, Placebo oral capsule; Drug
Lead sponsor: Colleen Stockdale; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pain, Quality of Life
Interventions: Gralise; Drug
Lead sponsor: Chicago Anesthesia Pain Specialists; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alcoholism, Alcohol Dependence
Interventions: Gabapentin 900mg, behavioral counseling, placebo, gabapentin 1800mg; Drug · Behavioral
Lead sponsor: The Scripps Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Hot Flashes
Interventions: Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo; Drug
Lead sponsor: Depomed; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 45
States / cities: Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 40 more

Conditions: Complex Regional Pain Syndrome I (CRPS I)
Interventions: Gabapentin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Post-laminectomy Pain Syndrome
Interventions: Gralise®, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Restless Legs Syndrome
Interventions: GEn (XP13512/GSK1838262), Placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Opioid-use Disorder, Alcohol Use Disorder
Interventions: Gabapentin; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 59 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Cigarette Smoking, Tobacco Use
Interventions: Placebo, Gabapentin - 1800 mg/day, Gabapentin - 2700 mg/day; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Spinal Cord Injuries
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Restless Legs Syndrome
Interventions: XP13512, Diphenhydramine, Placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Pain, Total Knee Replacement, Total Hip Replacement
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

To Evaluate if the Medication Gabapentin Lessens Vulvar Pain

Once Daily Gabapentin in the Treatment of Post Amputation Pain

Gabapentin Treatment of Alcohol Dependence

Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.

Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)

GRASSP: Gralise® for Spine Surgery Pain

Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome

Medication Development for Opioid and Alcohol Abuse

Gabapentin for Smoking Cessation

Feasibility of Early Gabapentin as an Intervention for Neurorecovery

Simulated Driving Study in Restless Legs Syndrome

Predicting, Understanding and Speeding Recovery After TKA